Combining anti-PDGF, anti-VEGF potential next step in stalling wet AMD progression

Hasson, Matt
February 2013
Ocular Surgery News;2/25/2013, Vol. 31 Issue 4, p32
Academic Journal
The article reports that anti platelet derived growth factor (anti-PDGF) and anti vascular endothelial growth factor (anti-VEGF) which show that both combination treatments arms meet the pre-specified primary endpoint of superiority.


Related Articles

  • Combining anti-PDGF with anti-VEGF may improve visual acuity, reduce AMD treatment burden.  // Ocular Surgery News;7/25/2012, Vol. 30 Issue 14, Special section p1 

    The article states that the complex disease process 'Advanced age-related macular degeneration be treated by modulating two factors 'VEGF' and 'PDGF'.When anti VEGF therapy is combined with anti platelet derived growth factor aptamer it leads to a better visual outcome.The limitation of anti...

  • Woman complains of gradual decrease in vision. Renz, Jennifer; Duker, Jay S. // Ocular Surgery News;6/10/2014, Vol. 32 Issue 11, p34 

    The article describes the case of a 65 year old woman who complained of gradually decreasing vision and was diagnosed with neovascular age-related macular generation receiving intravitreal ranibuzumab every 5 to 6 weeks for the last 3 years bilaterally. Topics discussed include her ocular...

  • Repeated anti-VEGF injections may alter RNFL thickness. Biro, Ashley // Ocular Surgery News;2/10/2013, Vol. 31 Issue 3, p21 

    The article discusses that anti vascular endothelial growth factor (anti-VEGF) injections can alter retinal nerve fiber layer (RNFL) thickness.

  • Anti-VEGF therapy effective in treatment of myopic CNV.  // Ocular Surgery News;6/10/2012, Vol. 30 Issue 11, p18 

    No abstract available.

  • Erythropoietin slows progressive geographic atrophy in dry AMD eyes. Harrison, Laird // Ophthalmology Times;Oct2015, Vol. 40 Issue 16, p50 

    The article discusses the ability of erythropoietin to slow down the progression of geographic atrophy in patients with age-related macular degeneration (AMD). Topics covered include the impact of the medicine on hindering vision loss in patients with the health condition. Also mentioned is the...

  • Judicious use of anti-VEGF agents advised as 'reasonable'. Reichel, Elias // Ocular Surgery News;3/10/2011, Vol. 29 Issue 5, p18 

    The article reports on the reasonable advice on the judicious use of anti-vascular endothelial growth factors (VEGF) agents for age-related macular degeneration (AMD) treatment.

  • Anti-PDGF fails to meet primary AMD endpoint in phase III trials.  // Ophthalmology Times;Dec2016, Vol. 41 Issue 20, p32 

    The article presents information on the failure of biopharmaceutical firm Ophthotech Corp. to achieve the primary endpoint of age-related macular degeneration (AMD) in its phase III trials.

  • Inhibiting VEGF and PDGF to Treat AMD. Mones, Jordi // Review of Ophthalmology;Sep2011, Vol. 18 Issue 9, p56 

    The article discusses the use of anti-vascular endothelial growth factor (Anti-VEGF) agents and platelet-derived growth factor (PDGF) antagonists in treating age-related macular degeneration (AMD). It notes that anti-VEGF agents enhances the vision of patients with wet AMD. It cites that the...

  • Treat-and-extend treatment with 0.5 mg ranibizumab vs. monthly treatment with 0.5 mg ranibizumab (T-REX).  // Ocular Surgery News;5/25/2013, Vol. 31 Issue 10, p41 

    The article describes the results of a clinical trial of the safety, tolerability, and effectiveness of ranibizumab from Genentech in the treatment of patients with wet age-related macular degeneration. The study compares the efficacy of the drug when administered in the patients monthly or...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics